DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that Neoprobe has been granted authorization by FDA to commence patient enrollment in two Phase 1 clinical studies to evaluate the safety and efficacy of Lymphoseek®, a lymphatic tissue targeting agent being developed by the Company, in prostate and colon cancers. The two studies are being undertaken at the University of California, San Diego and are being funded by grants provided by the National Cancer Institute.
